Targeting the sarcomere to correct muscle function

Nature Reviews Drug Discovery

Volumn 14, Issue 5, 2015, Pages 313-328

  Hwang, Peter M ^a   Sykes, Brian D ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,5,6 TETRAHYDRO 5 METHYL 6 PHENYL 3,6 METHANO 1,5 BENZODIAZOCINE 2,4 DIONE; 5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; BEPRIDIL; BLEBBISTATIN; CALCIUM SENSITIZER; DIACETYL OXIME; LEVOSIMENDAN; MYOSIN; N (6 AMINOHEXYL) 5 CHLORO 1 NAPHTHALENESULFONAMIDE; OMECAMTIV MECARBIL; PHOSPHODIESTERASE III; PIMOBENDAN; PLACEBO; SENAZODAN; TIRASEMTIV; TROPONIN; MUSCLE PROTEIN;

ACUTE HEART FAILURE; CALCIUM MOBILIZATION; CELL FUNCTION; CHRONIC DISEASE; DRUG EFFECT; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME MECHANISM; GENE MUTATION; HUMAN; MUSCLE CONTRACTION; MUSCLE RELAXATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SARCOMERE; SIGNAL TRANSDUCTION; SYSTOLIC HEART FAILURE; ANIMAL; CARDIOMYOPATHIES; HEART FAILURE; METABOLISM; MUSCULAR DISEASES; NEUROMUSCULAR DISEASES; PATHOPHYSIOLOGY; PHYSIOLOGY; SKELETAL MUSCLE;

ANIMALS; CARDIOMYOPATHIES; HEART FAILURE; HUMANS; MUSCLE CONTRACTION; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR DISEASES; NEUROMUSCULAR DISEASES; SARCOMERES; SIGNAL TRANSDUCTION;

EID: 84929026766     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4554     Document Type: Review

References (202)

1. Huxley, H. & Hanson, J. Changes in the cross-striations of muscle during contraction and stretch and their structural interpretation. Nature 173, 973-976 (1954
2. Knoll, R. & Marston, S. On mechanosensation, acto/myosin interaction, and hypertrophy. Trends Cardiovasc. Med. 22, 17-22 (2012)
3. Kolb, S. J. & Kissel, J. T. Spinal muscular atrophy: a timely review. Arch. Neurol. 68, 979-984 (2011)
4. Rowland, L. P. & Shneider, N. A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 344, 1688-1700 (2001)
5. Shefner, J. M., Wolff, A. A. & Meng, L. The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 14, 582-585 (2013)
6. Chou, R., Peterson, K. & Helfand, M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J. Pain Symptom Manage. 28, 140-175 (2004)
7. Desai, A. S. & Stevenson, L. W. Rehospitalization for heart failure: predict or prevent? Circulation 126, 501-506 (2012)
8. Curtis, J. P. et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J. Am. Coll. Cardiol. 42, 736-742 (2003)
9. Lam, C. S., Donal, E., Kraigher-Krainer, E. & Vasan, R. S. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur. J. Heart Fail. 13, 18-28 (2011)
10. Lovelock, J. D. et al. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ. Res. 110, 841-850 (2012)
11. Boswell-Smith, V., Spina, D. & Page, C. P. Phosphodiesterase inhibitors. Br. J. Pharmacol. 14, S252-S257 (2006)
12. Bers, D. M. Calcium fluxes involved in control of cardiac myocyte contraction. Circ. Res. 87, 275-281 (2000)
13. Marks, A. R. Calcium cycling proteins and heart failure: mechanisms and therapeutics. J. Clin. Invest. 123, 46-52 (2013)
14. Gailly, P. New aspects of calcium signaling in skeletal muscle cells: implications in Duchenne muscular dystrophy. Biochim. Biophys. Acta 1600, 38-44 (2002)
15. Stanley, W. C., Recchia, F. A. & Lopaschuk, G. D. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85, 1093-1129 (2005)
16. Egan, B. & Zierath, J. R. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell. Metab. 17, 162-184 (2013)
17. McCarthy, J. J. & Esser, K. A. Anabolic and catabolic pathways regulating skeletal muscle mass. Curr. Opin. Clin. Nutr. Metab. Care 13, 230-235 (2010)
18. Frey, N. & Olson, E. N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol. 65, 45-79 (2003)
19. Barry, S. P., Davidson, S. M. & Townsend, P. A. Molecular regulation of cardiac hypertrophy. Int. J. Biochem. Cell Biol. 40, 2023-2039 (2008)
20. Endoh, M. Amrinone, forerunner of novel cardiotonic agents, caused paradigm shift of heart failure pharmacotherapy. Circ. Res. 113, 358-361 (2013)
21. Sato, S., Talukder, M. A., Sugawara, H., Sawada, H. & Endoh, M. Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J. Mol. Cell Cardiol 30, 1115-1128 (1998)
22. Kawabata, Y. & Endoh, M. Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ. Res. 72, 597-606 (1993)
23. Miller, D. J. & Steele, D. S. The 'calcium sensitising' effects of ORG30029 in saponin- or Triton-skinned rat cardiac muscle. Br. J. Pharmacol. 100, 843-849 (1990)
24. Solaro, R. J., Pang, D. C. & Briggs, F. N. The purification of cardiac myofibrils with Triton X-100. Biochim. Biophys. Acta 245, 259-262 (1971
25. Fiske, C. H. & Subbarow, Y. The colorimetric determination of phosphorus. J. Biol. Chem. 66, 375-400 (1925
26. Papp, Z. et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int. J. Cardiol. 159, 82-87 (2012)
27. Boyle, K. L. & Leech, E. A review of the pharmacology and clinical uses of pimobendan. J. Vet. Emerg. Crit. Care (San Antonio) 22, 398-408 (2012)
28. van Meel, J. C., Zimmermann, R., Diederen, W., Erdman, E. & Mrwa, U. Increase in calcium sensitivity of cardiac myofibrils contributes to the cardiotonic action of sulmazole. Biochem. Pharmacol. 37, 213-220 (1988
29. Bethke, T. et al. High selectivity for inhibition of phosphodiesterase III and positive inotropic effects of MCI-154 in guinea pig myocardium. J. Cardiovasc. Pharmacol. 21, 847-855 (1993)
30. Sugawara, H. et al. Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 3rd communication: stereoselectivity of the enantiomers in cardiovascular effects. Arzneimittelforschung 49, 412-419 (1999)
31. de Boer, J. et al. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br. J. Pharmacol. 106, 1028-1034 (1992)
32. Keravis, T. & Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br. J. Pharmacol. 165, 1288-1305 (2012)
33. Bethke, T. et al. Phosphodiesterase inhibition by enoximone in preparations from nonfailing and failing human hearts. Arzneimittelforschung 42, 437-445 (1992)
34. Szilagyi, S. et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur. J. Pharmacol. 486, 67-74 (2004)
35. Mika, D. et al. Differential regulation of cardiac excitation-contraction coupling by cAMP phosphodiesterase subtypes. Cardiovasc. Res. 100, 336-346 (2013)
36. Roubille, F. & Tardif, J. C. New therapeutic targets in cardiology: heart failure and arrhythmia: HCN channels. Circulation 127, 1986-1996 (2013)
37. Perera, R. K. & Nikolaev, V. O. Compartmentation of cAMP signalling in cardiomyocytes in health and disease. Acta Physiol. (Oxf.) 207, 650-662 (2013)
38. Cazorla, O., Lucas, A., Poirier, F., Lacampagne, A. & Lezoualc'h, F. The cAMP binding protein Epac regulates cardiac myofilament function. Proc. Natl Acad. Sci. USA 106, 14144-14149 (2009)
39. Wendt, I. R. & Stephenson, D. G. Effects of caffeine on Ca-Activated force production in skinned cardiac and skeletal muscle fibres of the rat. Pflugers Arch. 398, 210-216 (1983
40. Parsons, W. J., Ramkumar, V. & Stiles, G. L. The new cardiotonic agent sulmazole is an A1 adenosine receptor antagonist and functionally blocks the inhibitory regulator, Gi. Mol. Pharmacol. 33, 441-448 (1988
41. Kitada, Y., Kobayashi, M., Narimatsu, A. & Ohizumi, Y. Potent stimulation of myofilament force and adenosine triphosphatase activity of canine cardiac muscle through a direct enhancement of troponin C Ca++ binding by MCI-154, a novel cardiotonic agent. J. Pharmacol. Exp. Ther. 250, 272-277 (1989
42. Haikala, H. et al. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J. Mol. Cell Cardiol. 27, 1859-1866 (1995)
43. Pollesello, P. et al. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J. Biol. Chem. 269, 28584-28590 (1994)
44. Kleerekoper, Q. & Putkey, J. A. Drug binding to cardiac troponin C. J. Biol. Chem. 274, 23932-23939 (1999)
45. Sorsa, T., Pollesello, P., Permi, P., Drakenberg, T. & Kilpelainen, I. Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides. J. Mol. Cell Cardiol. 35, 1055-1061 (2003)
46. Robertson, I. M., Baryshnikova, O. K., Li, M. X. & Sykes, B. D. Defining the binding site of levosimendan and its analogues in a regulatory cardiac troponin C-troponin I complex. Biochemistry 47, 7485-7495 (2008)
47. Sorsa, T. et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J. Biol. Chem. 276, 9337-9343 (2001)
48. Orstavik, O. et al. PDE3-inhibition by levosimendan is sufficient to account for its inotropic effect in failing human heart. Br. J. Pharmacol. 171, 5169-5181 (2014)
49. Bodi, A., Szilagyi, S., Edes, I. & Papp, Z. The cardiotonic effects of levosimendan in guinea pig hearts are modulated by β-Adrenergic stimulation. Gen. Physiol. Biophys. 22, 313-327 (2003)
50. Erdei, N., Papp, Z., Pollesello, P., Edes, I. & Bagi, Z. The levosimendan metabolite OR-1896 elicits vasodilation by activating the KATP and BKCa channels in rat isolated arterioles. Br. J. Pharmacol. 148, 696-702 (2006)
51. Yoshida, H. et al. A phosphodiesterase 3 inhibitor, K-134, improves hindlimb skeletal muscle circulation in rat models of peripheral arterial disease. Atherosclerosis 221, 84-90 (2012)
52. Nieminen, M. S. et al. Levosimendan: current data, clinical use and future development. Heart Lung Vessel 5, 227-245 (2013)
53. Landoni, G. et al. Effects of levosimendan on mortality and hospitalization. A meta-Analysis of randomized controlled studies. Crit. Care Med. 40, 634-646 (2012)
54. Mebazaa, A. et al. Levosimendan versus dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 297, 1883-1891 (2007)
55. Packer, M. et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 1, 103-111 (2013)
56. Packer, M. et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. 325, 1468-1475 (1991)
57. Amsallem, E., Kasparian, C., Haddour, G., Boissel, J. P. & Nony, P. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst. Rev. 1, CD002230 (2005)
58. Yancy, C. W. et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol 62, e147-e239 (2013)
59. McMurray, J. J. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 33, 1787-1847 (2012)
60. Baudenbacher, F. et al. Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice. J. Clin. Invest. 118, 3893-3903 (2008)
61. Parry, D. A. & Squire, J. M. Structural role of tropomyosin in muscle regulation: analysis of the X-ray diffraction patterns from relaxed and contracting muscles. J. Mol. Biol. 75, 33-55 (1973
62. Li, M. X., Spyracopoulos, L. & Sykes, B. D. Binding of cardiac troponin-I147-163 induces a structural opening in human cardiac troponin-C. Biochemistry 38, 8289-8298 (1999)
63. Rieck, D. C., Li, K. L., Ouyang, Y., Solaro, R. J. & Dong, W. J. Structural basis for the in situ Ca2+ sensitization of cardiac troponin C by positive feedback from force-generating myosin cross-bridges. Arch. Biochem. Biophys. 537, 198-209 (2013)
64. Sweeney, H. L. & Houdusse, A. Structural and functional insights into the myosin motor mechanism. Annu. Rev. Biophys. 39, 539-557 (2010)
65. Webb, M. et al. The myosin duty ratio tunes the calcium sensitivity and cooperative activation of the thin filament. Biochemistry 52, 6437-6444 (2013)
66. Margossian, S. S. & Lowey, S. Preparation of myosin and its subfragments from rabbit skeletal muscle. Methods Enzymol. 85, 55-71 (1982
67. Pardee, J. D. & Spudich, J. A. Purification of muscle actin. Methods Enzymol. 85, 164-181 (1982
68. Smillie, L. B. Preparation and identification of α- and β-tropomyosins. Methods Enzymol. 85, 234-241 (1982
69. Potter, J. D. Preparation of troponin and its subunits. Methods Enzymol. 85, 241-263 (1982
70. Spudich, J. A. & Watt, S. The regulation of rabbit skeletal muscle contraction. I. Biochemical studies of the interaction of the tropomyosin-troponin complex with actin and the proteolytic fragments of myosin. J. Biol. Chem. 246, 4866-4871 (1971
71. Malik, F. I. & Morgan, B. P. Cardiac myosin activation part 1: from concept to clinic. J. Mol. Cell Cardiol 51, 454-461 (2011)
72. Malik, F. I. et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 331, 1439-1443 (2011)
73. Wang, Y., Ajtai, K. & Burghardt, T. P. Analytical comparison of natural and pharmaceutical ventricular myosin activators. Biochemistry 53, 5298-5306 (2014)
74. Wolska, B. M. et al. CGP-48506 increases contractility of ventricular myocytes and myofilaments by effects on actin-myosin reaction. Am. J. Physiol. 270, H24-H32 (1996)
75. Palmer, S., Di Bello, S., Davenport, S. L. & Herzig, J. W. The novel inotropic agent CGP 48506 alters force primarily by Ca2+-independent mechanisms in porcine skinned trabeculae. Cardiovasc. Res. 32, 411-421 (1996)
76. Brixius, K., Mehlhorn, U., Bloch, W. & Schwinger, R. H. Different effect of the Ca2+ sensitizers EMD 57033 and CGP 48506 on cross-bridge cycling in human myocardium. J. Pharmacol. Exp. Ther. 295, 1284-1290 (2000)
77. Ferroni, C. et al. A novel positive inotropic substance enhances contractility without increasing the Ca2+ transient in rat myocardium. J. Mol. Cell Cardiol. 23, 325-331 (1991)
78. Solaro, R. J. et al. Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circ. Res. 73, 981-990 (1993)
79. Radke, M. B. et al. Small molecule-mediated refolding and activation of myosin motor function. Elife 3, e01603 (2014)
80. Bond, L. M., Tumbarello, D. A., Kendrick-Jones, J. & Buss, F. Small-molecule inhibitors of myosin proteins. Future Med. Chem. 5, 41-52 (2013)
81. Allingham, J. S., Smith, R. & Rayment, I. The structural basis of blebbistatin inhibition and specificity for myosin II. Nature Struct. Mol. Biol. 12, 378-379 (2005)
82. Kovacs, M., Toth, J., Hetenyi, C., Malnasi-Csizmadia, A. & Sellers, J. R. Mechanism of blebbistatin inhibition of myosin II. J. Biol. Chem. 279, 35557-35563 (2004)
83. Rodriguez, H. M. et al. Modulation of the cardiac sarcomere by a small molecule agent MYK0000461: a potential therapeutic for the treatment of genetic hypertrophic cardiomyopathies. Biophys. J. 106, 562a (2015)
84. Teerlink, J. R. et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet 378, 667-675 (2011)
85. Cleland, J. G. et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 378, 676-683 (2011)
86. Teerlink, J. R. & McDonagh, T. ATOMIC-AHF: acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: results from ATOMIC-AHF. European Society of Cardiology [online], http: //www.escardio.org/congresses/esc-2013/ congress-reports/Pages/709-ATOMIC-AHF.aspx#. VNzc9PmsX9l (2013)
87. Li, M. X. et al. Kinetic studies of calcium and cardiac troponin I peptide binding to human cardiac troponin C using NMR spectroscopy. Eur. Biophys. J. 31, 245-256 (2002)
88. Takeda, S., Yamashita, A., Maeda, K. & Maeda, Y. Structure of the core domain of human cardiac troponin in the Ca2+-saturated form. Nature 424, 35-41 (2003)
89. Davis, J. P. et al. Effects of thin and thick filament proteins on calcium binding and exchange with cardiac troponin C. Biophys. J. 92, 3195-3206 (2007)
90. Pineda-Sanabria, S. E., Julien, O. & Sykes, B. D. Versatile cardiac troponin chimera for muscle protein structural biology and drug discovery. ACS Chem. Biol. 9, 2121-2130 (2014)
91. Itoh, H., Tanaka, T., Mitani, Y. & Hidaka, H. The binding of the calcium channel blocker, bepridil, to calmodulin. Biochem. Pharmacol. 35, 217-220 (1986
92. Solaro, R. J., Bousquet, P. & Johnson, J. D. Stimulation of cardiac myofilament force, ATPase activity and troponin C Ca++ binding by bepridil. J. Pharmacol. Exp. Ther. 238, 502-507 (1986
93. Li, Y., Love, M. L., Putkey, J. A. & Cohen, C. Bepridil opens the regulatory N-terminal lobe of cardiac troponin C. Proc. Natl Acad. Sci. USA 97, 5140-5145 (2000)
94. Wang, X., Li, M. X. & Sykes, B. D. Structure of the regulatory N-domain of human cardiac troponin C in complex with human cardiac troponin I147-163 and bepridil. J. Biol. Chem. 277, 31124-31133 (2002)
95. Vinogradova, M. V. et al. Ca2+-regulated structural changes in troponin. Proc. Natl Acad. Sci. USA 102, 5038-5043 (2005)
96. Silver, P. J., Pinto, P. B. & Dachiw, J. Modulation of vascular and cardiac contractile protein regulatory mechanisms by calmodulin inhibitors and related compounds. Biochem. Pharmacol. 35, 2545-2551 (1986
97. Adhikari, B. B. & Wang, K. Interplay of troponin-And myosin-based pathways of calcium activation in skeletal and cardiac muscle: the use of W7 as an inhibitor of thin filament activation. Biophys. J. 86, 359-370 (2004)
98. Li, M. X., Hoffman, R. M. & Sykes, B. D. Interaction of cardiac troponin C with calmodulin antagonist [corrected] W7 in the presence of three functional regions of cardiac troponin I. Biochemistry 45, 9833-9840 (2006)
99. Oleszczuk, M., Robertson, I. M., Li, M. X. & Sykes, B. D. Solution structure of the regulatory domain of human cardiac troponin C in complex with the switch region of cardiac troponin I and W7: the basis of W7 as an inhibitor of cardiac muscle contraction. J. Mol. Cell Cardiol. 48, 925-933 (2010)
100. Russell, A. J. et al. Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nature Med. 18, 452-455 (2012)
101. Bauer, T. A. et al. Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease. Vasc. Med. 19, 297-306 (2014)
102. Shefner, J. M., Watson, M. L., Meng, L. & Wolff, A. A. A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 14, 574-581 (2013)
103. de Winter, J. M. et al. Troponin activator augments muscle force in nemaline myopathy patients with nebulin mutations. J. Med. Genet. 50, 383-392 (2013)
104. Spyracopoulos, L. et al. Calcium-induced structural transition in the regulatory domain of human cardiac troponin C. Biochemistry 36, 12138-12146 (1997)
105. Herron, T. J. et al. Ca2+-independent positive molecular inotropy for failing rabbit and human cardiac muscle by α-myosin motor gene transfer. FASEB J. 24, 415-424 (2010)
106. Day, S. M. et al. Histidine button engineered into cardiac troponin I protects the ischemic and failing heart. Nature Med. 12, 181-189 (2006)
107. Merkulov, S., Chen, X., Chandler, M. P. & Stelzer, J. E. In vivo cardiac myosin binding protein C gene transfer rescues myofilament contractile dysfunction in cardiac myosin binding protein C null mice. Circ. Heart Fail. 5, 635-644 (2012)
108. Mearini, G. et al. Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice. Nature Commun. 5, 5515 (2014)
109. Mamidi, R., Li, J., Gresham, K. S. & Stelzer, J. E. Cardiac myosin binding protein-C: a novel sarcomeric target for gene therapy. Pflugers Arch. 466, 225-230 (2014)
110. Maron, B. J., Maron, M. S. & Semsarian, C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J. Am. Coll. Cardiol. 60, 705-715 (2012)
111. Sen-Chowdhry, S., Syrris, P. & McKenna, W. J. Genetics of restrictive cardiomyopathy. Heart Fail. Clin. 6, 179-186 (2010)
112. Sanbe, A. Dilated cardiomyopathy: a disease of the myocardium. Biol. Pharm. Bull. 36, 18-22 (2013)
113. McNally, E. M., Golbus, J. R. & Puckelwartz, M. J. Genetic mutations and mechanisms in dilated cardiomyopathy. J. Clin. Invest. 123, 19-26 (2013)
114. Goldfarb, L. G. & Dalakas, M. C. Tragedy in a heartbeat: malfunctioning desmin causes skeletal and cardiac muscle disease. J. Clin. Invest. 119, 1806-1813 (2009)
115. Teekakirikul, P., Kelly, M. A., Rehm, H. L., Lakdawala, N. K. & Funke, B. H. Inherited cardiomyopathies: molecular genetics and clinical genetic testing in the postgenomic era. J. Mol. Diagn. 15, 158-170 (2013)
116. Laing, N. G. & Nowak, K. J. When contractile proteins go bad: the sarcomere and skeletal muscle disease. Bioessays 27, 809-822 (2005)
117. Tajsharghi, H. & Oldfors, A. Myosinopathies: pathology and mechanisms. Acta Neuropathol. 125, 3-18 (2013)
118. Wallgren-Pettersson, C., Sewry, C. A., Nowak, K. J. & Laing, N. G. Nemaline myopathies. Semin. Pediatr. Neurol. 18, 230-238 (2011)
119. Lehtokari, V. L. et al. Identification of 45 novel mutations in the nebulin gene associated with autosomal recessive nemaline myopathy. Hum. Mutat. 27, 946-956 (2006)
120. Lawlor, M. W. et al. Novel mutations in NEB cause abnormal nebulin expression and markedly impaired muscle force generation in severe nemaline myopathy. Skelet. Muscle 1, 23 (2011)
121. Claeys, K. G. & Fardeau, M. Myofibrillar myopathies. Handb. Clin. Neurol. 113, 1337-1342 (2013)
122. de Tombe, P. P. et al. Myofilament length dependent activation. J. Mol. Cell Cardiol. 48, 851-858 (2010)
123. Kontrogianni-Konstantopoulos, A., Ackermann, M. A., Bowman, A. L., Yap, S. V. & Bloch, R. J. Muscle giants: molecular scaffolds in sarcomerogenesis. Physiol. Rev. 89, 1217-1267 (2009)
124. Mateja, R. D. & de Tombe, P. P. Myofilament length-dependent activation develops within 5 ms in guinea-pig myocardium. Biophys. J. 103, L13-L15 (2012)
125. Zhang, Z. et al. Comparison of the Young-Laplace law and finite element based calculation of ventricular wall stress: implications for postinfarct and surgical ventricular remodeling. Ann. Thorac. Surg. 91, 150-156 (2011)
126. Rudolf, R. et al. Alterations of cAMP-dependent signaling in dystrophic skeletal muscle. Front. Physiol. 4, 290 (2013)
127. Lygren, B. & Tasken, K. Compartmentalized cAMP signalling is important in the regulation of Ca2+ cycling in the heart. Biochem. Soc. Trans. 34, 489-491 (2006)
128. Boontje, N. M. et al. Enhanced myofilament responsiveness upon β-Adrenergic stimulation in post-infarct remodeled myocardium. J. Mol. Cell Cardiol. 50, 487-499 (2011)
129. Gautel, M., Zuffardi, O., Freiburg, A. & Labeit, S. Phosphorylation switches specific for the cardiac isoform of myosin binding protein-C: a modulator of cardiac contraction? EMBO J. 14, 1952-1960 (1995)
130. Gruen, M. Prinz, H. & Gautel, M. cAPK-phosphorylation controls the interaction of the regulatory domain of cardiac myosin binding protein C with myosin-S2 in an on-off fashion. FEBS Lett. 453, 254-259 (1999)
131. Kruger, M. & Linke, W. A. Protein kinase-A phosphorylates titin in human heart muscle and reduces myofibrillar passive tension. J. Muscle Res. Cell. Motil. 27, 435-444 (2006)
132. Solaro, R. J., Moir, A. J. & Perry, S. V. Phosphorylation of troponin I and the inotropic effect of adrenaline in the perfused rabbit heart. Nature 262, 615-617 (1976
133. Wijnker, P. J. et al. Impact of site-specific phosphorylation of protein kinase A sites Ser23 and Ser24 of cardiac troponin I in human cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 304, H260-H268 (2013)
134. Hamdani, N. et al. Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction. Eur. Heart J. 30, 1863-1872 (2009)
135. van Dijk, S. J. et al. A piece of the human heart: variance of protein phosphorylation in left ventricular samples from end-stage primary cardiomyopathy patients. J. Muscle Res. Cell. Motil. 30, 299-302 (2009)
136. MacIntosh, B. R., Holash, R. J. & Renaud, J. M. Skeletal muscle fatigue - regulation of excitation-contraction coupling to avoid metabolic catastrophe. J. Cell Sci. 125, 2105-2114 (2012)
137. Kamm, K. E. & Stull, J. T. Signaling to myosin regulatory light chain in sarcomeres. J. Biol. Chem. 286, 9941-9947 (2011)
138. Scruggs, S. B. & Solaro, R. J. The significance of regulatory light chain phosphorylation in cardiac physiology. Arch. Biochem. Biophys. 510, 129-134 (2011)
139. Grimm, M. et al. Key role of myosin light chain (MLC) kinase-mediated MLC2a phosphorylation in the α1-Adrenergic positive inotropic effect in human atrium. Cardiovasc. Res. 65, 211-220 (2005)
140. Flashman, E., Redwood, C., Moolman-Smook, J. & Watkins, H. Cardiac myosin binding protein C: its role in physiology and disease. Circ. Res. 94, 1279-1289 (2004)
141. Lowey, S., Slayter, H. S., Weeds, A. G. & Baker, H. Substructure of the myosin molecule. I. Subfragments of myosin by enzymic degradation. J. Mol. Biol. 42, 1-29 (1969
142. Al-Khayat, H. A., Kensler, R. W., Squire, J. M., Marston, S. B. & Morris, E. P. Atomic model of the human cardiac muscle myosin filament. Proc. Natl Acad. Sci. USA 110, 318-323 (2013)
143. Craig, R. & Woodhead, J. L. Structure and function of myosin filaments. Curr. Opin. Struct. Biol. 16, 204-212 (2006)
144. Weeds, A. G. & Lowey, S. Substructure of the myosin molecule. II. The light chains of myosin. J. Mol. Biol. 61, 701-725 (1971
145. Freiburg, A. & Gautel, M. A molecular map of the interactions between titin and myosin-binding protein C. Implications for sarcomeric assembly in familial hypertrophic cardiomyopathy. Eur. J. Biochem. 235, 317-323 (1996)
146. Miyamoto, C. A., Fischman, D. A. & Reinach, F. C. The interface between MyBP-C and myosin: site-directed mutagenesis of the CX myosin-binding domain of MyBP-C. J. Muscle Res. Cell. Motil. 20, 703-715 (1999)
147. Bhuiyan, M. S., Gulick, J., Osinska, H., Gupta, M. & Robbins, J. Determination of the critical residues responsible for cardiac myosin binding protein C's interactions. J. Mol. Cell Cardiol. 53, 838-847 (2012)
148. Sousa, D. R., Stagg, S. M. & Stroupe, M. E. Cryo-EM structures of the actin: tropomyosin filament reveal the mechanism for the transition from C- to M-state. J. Mol. Biol. 425, 4544-4555 (2013)
149. White, S. P., Cohen, C. & Phillips, G. N. J. Structure of co-crystals of tropomyosin and troponin. Nature 325, 826-828 (1987
150. Gourinath, S. et al. Crystal structure of scallop myosin s1 in the pre-power stroke state to 2.6 Å resolution: flexibility and function in the head. Structure 11, 1621-1627 (2003)
151. Behrmann, E. et al. Structure of the rigor actin-tropomyosin-myosin complex. Cell 150, 327-338 (2012)
152. Sia, S. K. et al. Structure of cardiac muscle troponin C unexpectedly reveals a closed regulatory domain. J. Biol. Chem. 272, 18216-18221 (1997)
153. Eichmuller, C. & Skrynnikov, N. R. A new amide proton R1ρ experiment permits accurate characterization of microsecond time-scale conformational exchange. J. Biomol. NMR 32, 281-293 (2005)
154. Geisterfer-Lowrance, A. A. et al. A molecular basis for familial hypertrophic cardiomyopathy: a β cardiac myosin heavy chain gene missense mutation. Cell 62, 999-1006 (1990)
155. Hernandez, O. M., Jones, M., Guzman, G. & Szczesna-Cordary, D. Myosin essential light chain in health and disease. Am. J. Physiol. Heart Circ. Physiol. 292, H1643-H1654 (2007)
156. Poetter, K. et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nature Genet. 13, 63-69 (1996)
157. Ha, K. et al. MYBPC1 mutations impair skeletal muscle function in zebrafish models of arthrogryposis. Hum. Mol. Genet. 22, 4967-4977 (2013)
158. Schlossarek, S., Mearini, G. & Carrier, L. Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities. J. Mol. Cell Cardiol. 50, 613-620 (2011)
159. Marston, S., Copeland, O., Gehmlich, K., Schlossarek, S. & Carrier, L. How do MYBPC3 mutations cause hypertrophic cardiomyopathy? J. Muscle Res. Cell. Motil. 33, 75-80 (2012)
160. Watkins, H. et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nature Genet. 11, 434-437 (1995)
161. Herman, D. S. et al. Truncations of titin causing dilated cardiomyopathy. N. Engl. J. Med. 366, 619-628 (2012)
162. Chauveau, C. et al. Recessive TTN truncating mutations define novel forms of core myopathy with heart disease. Hum. Mol. Genet. 23, 980-991 (2013)
163. Wang, K., McClure, J. & Tu, A. Titin: major myofibrillar components of striated muscle. Proc. Natl Acad. Sci. USA 76, 3698-3702 (1979
164. Nowak, K. J. et al. Mutations in the skeletal muscle α-Actin gene in patients with actin myopathy and nemaline myopathy. Nature Genet. 23, 208-212 (1999)
165. Mogensen, J. et al. Clinical and genetic characteristics of β cardiac actin gene mutations in hypertrophic cardiomyopathy. J. Med. Genet. 41, e10 (2004)
166. Watkins, H. et al. Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy. N. Engl. J. Med. 332, 1058-1064 (1995)
167. Donner, K. et al. Mutations in the β-tropomyosin (TPM2) gene-A rare cause of nemaline myopathy. Neuromuscul. Disord. 12, 151-158 (2002)
168. Sung, S. S. et al. Mutations in genes encoding fast-twitch contractile proteins cause distal arthrogryposis syndromes. Am. J. Hum. Genet. 72, 681-690 (2003)
169. Kee, A. J. & Hardeman, E. C. Tropomyosins in skeletal muscle diseases. Adv. Exp. Med. Biol. 644, 143-157 (2008)
170. Laing, N. G. et al. A mutation in the β tropomyosin gene TPM3 associated with autosomal dominant nemaline myopathy. Nature Genet. 9, 75-79 (1995)
171. Johnston, J. J. et al. A novel nemaline myopathy in the Amish caused by a mutation in troponin T1. Am. J. Hum. Genet. 67, 814-821 (2000)
172. Sung, S. S. et al. Mutations in TNNT3 cause multiple congenital contractures: a second locus for distal arthrogryposis type 2B. Am. J. Hum. Genet. 73, 212-214 (2003)
173. Kimura, A. et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nature Genet. 16, 379-382 (1997)
174. Landstrom, A. P. et al. Molecular and functional characterization of novel hypertrophic cardiomyopathy susceptibility mutations in TNNC1-encoded troponin C. J. Mol. Cell Cardiol 45, 281-288 (2008)
175. Purevjav, E. et al. Nebulette mutations are associated with dilated cardiomyopathy and endocardial fibroelastosis. J. Am. Coll. Cardiol 56, 1493-1502 (2010)
176. Pappas, C. T., Bliss, K. T., Zieseniss, A. & Gregorio, C. C. The nebulin family: an actin support group. Trends Cell Biol. 21, 29-37 (2011)
177. Millevoi, S. et al. Characterization of nebulette and nebulin and emerging concepts of their roles for vertebrate Z-discs. J. Mol. Biol. 282, 111-123 (1998)
178. Luther, P. K. The vertebrate muscle Z-disc: sarcomere anchor for structure and signalling. J. Muscle Res. Cell. Motil. 30, 171-185 (2009)
179. Chiu, C. et al. Mutations in α-Actinin-2 cause hypertrophic cardiomyopathy: a genome-wide analysis. J. Am. Coll. Cardiol. 55, 1127-1135 (2010)
180. Moreira, E. S. et al. Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin. Nature Genet. 24, 163-166 (2000)
181. Hayashi, T. et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J. Am. Coll. Cardiol. 44, 2192-2201 (2004)
182. Razinia, Z., Makela, T., Ylanne, J. & Calderwood, D. A. Filamins in mechanosensing and signaling. Annu. Rev. Biophys. 41, 227-246 (2012)
183. Vorgerd, M. et al. A mutation in the dimerization domain of filamin c causes a novel type of autosomal dominant myofibrillar myopathy. Am. J. Hum. Genet. 77, 297-304 (2005)
184. Faulkner, G. et al. FATZ, a filamin-, actinin-, and telethonin-binding protein of the Z-disc of skeletal muscle. J. Biol. Chem. 275, 41234-41242 (2000)
185. Osio, A. et al. Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy. Circ. Res. 100, 766-768 (2007)
186. Purevjav, E. et al. Molecular basis for clinical heterogeneity in inherited cardiomyopathies due to myopalladin mutations. Hum. Mol. Genet. 21, 2039-2053 (2012)
187. Meyer, T. et al. Novel mutations in the sarcomeric protein myopalladin in patients with dilated cardiomyopathy. Eur. J. Hum. Genet. 21, 294-300 (2013)
188. Bang, M. L. et al. Myopalladin, a novel 145-kilodalton sarcomeric protein with multiple roles in Z-disc and I-band protein assemblies. J. Cell Biol. 153, 413-427 (2001)
189. Salmikangas, P. et al. Myotilin, the limb-girdle muscular dystrophy 1A (LGMD1A) protein, cross-links actin filaments and controls sarcomere assembly. Hum. Mol. Genet. 12, 189-203 (2003)
190. Hauser, M. A. et al. Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum. Mol. Genet. 9, 2141-2147 (2000)
191. Selcen, D. & Engel, A. G. Mutations in myotilin cause myofibrillar myopathy. Neurology 62, 1363-1371 (2004)
192. von Nandelstadh, P. et al. A class III PDZ binding motif in the myotilin and FATZ families binds enigma family proteins: a common link for Z-disc myopathies. Mol. Cell. Biol. 29, 822-834 (2009)
193. Strach, K. et al. ZASPopathy with childhood-onset distal myopathy. J. Neurol. 259, 1494-1496 (2012)
194. Selcen, D. & Engel, A. G. Mutations in ZASP define a novel form of muscular dystrophy in humans. Ann. Neurol. 57, 269-276 (2005)
195. Vatta, M. et al. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J. Am. Coll. Cardiol. 42, 2014-2027 (2003)
196. Arimura, T. et al. A Cypher/ZASP mutation associated with dilated cardiomyopathy alters the binding affinity to protein kinase C. J. Biol. Chem. 279, 6746-6752 (2004)
197. Lin, C. et al. Cypher/ZASP is a novel A-kinase anchoring protein. J. Biol. Chem. 288, 29403-29413 (2013)
198. Limouze, J., Straight, A. F., Mitchison, T. & Sellers, J. R. Specificity of blebbistatin, an inhibitor of myosin II. J. Muscle Res. Cell. Motil. 25, 337-341 (2004)
199. Cheung, A. et al. A small-molecule inhibitor of skeletal muscle myosin II. Nature Cell Biol. 4, 83-88 (2002)
200. McKillop, D. F., Fortune, N. S., Ranatunga, K. W. & Geeves, M. A. The influence of 2, 3-butanedione 2-monoxime (BDM) on the interaction between actin and myosin in solution and in skinned muscle fibres. J. Muscle Res. Cell. Motil. 15, 309-318 (1994)
201. Kischel, P., Stevens, L. & Mounier, Y. Differential effects of bepridil on functional properties of troponin C in slow and fast skeletal muscles. Br. J. Pharmacol. 128, 767-773 (1999)
202. Robertson, I. M., Sun, Y. B., Li, M. X. & Sykes, B. D. A structural and functional perspective into the mechanism of Ca2+-sensitizers that target the cardiac troponin complex. J. Mol. Cell Cardiol. 49, 1031-1041 (2010